Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease

2021 ◽  
Author(s):  
Pratishtha Chatterjee ◽  
Steve Pedrini ◽  
Nicholas J. Ashton ◽  
Michelle Tegg ◽  
Kathryn Goozee ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Preclinical Alzheimer’S Disease ◽  
Plasma Biomarkers

3D Mapping of Verbal Memory in Clinical and Preclinical Alzheimer's Disease

2012 ◽  
Author(s):  
Jennifer A. Eastman ◽  
Kristy S. Hwang ◽  
Sona Babakchanian ◽  
Nicole Chow ◽  
Leslie Ramirez ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Verbal Memory ◽  
3D Mapping ◽  
Preclinical Alzheimer’S Disease

scholarly journals Disease progression modelling from preclinical Alzheimer’s disease (AD) to AD dementia

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Soo Hyun Cho ◽  
Sookyoung Woo ◽  
Changsoo Kim ◽  
Hee Jin Kim ◽  
Hyemin Jang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Disease Progression ◽  
Disease Assessment ◽  
Time Interval ◽  
Disease Course ◽  
Preclinical Alzheimer’S Disease ◽  
Apoe Ε4 ◽  
Preclinical Ad ◽  
Cognitive Subscale

AbstractTo characterize the course of Alzheimer’s disease (AD) over a longer time interval, we aimed to construct a disease course model for the entire span of the disease using two separate cohorts ranging from preclinical AD to AD dementia. We modelled the progression course of 436 patients with AD continuum and investigated the effects of apolipoprotein E ε4 (APOE ε4) and sex on disease progression. To develop a model of progression from preclinical AD to AD dementia, we estimated Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-cog 13) scores. When calculated as the median of ADAS-cog 13 scores for each cohort, the estimated time from preclinical AD to MCI due to AD was 7.8 years and preclinical AD to AD dementia was 15.2 years. ADAS-cog 13 scores deteriorated most rapidly in women APOE ε4 carriers and most slowly in men APOE ε4 non-carriers (p < 0.001). Our results suggest that disease progression modelling from preclinical AD to AD dementia may help clinicians to estimate where patients are in the disease course and provide information on variation in the disease course by sex and APOE ε4 status.

scholarly journals Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer’s Disease: Results from the Gothenburg H70 Birth Cohort Studies

2021 ◽  
Vol 79 (1) ◽  
pp. 225-235
Author(s):  
Maya Arvidsson Rådestig ◽  
Johan Skoog ◽  
Henrik Zetterberg ◽  
Jürgen Kern ◽  
Anna Zettergren ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Cohort Studies ◽  
Cognitive Performance ◽  
Birth Cohort ◽  
Population Based ◽  
Tau Pathology ◽  
Preclinical Alzheimer’S Disease ◽  
Preclinical Ad

Background: We have previously shown that older adults with preclinical Alzheimer’s disease (AD) pathology in cerebrospinal fluid (CSF) had slightly worse performance in Mini-Mental State Examination (MMSE) than participants without preclinical AD pathology. Objective: We therefore aimed to compare performance on neurocognitive tests in a population-based sample of 70-year-olds with and without CSF AD pathology. Methods: The sample was derived from the population-based Gothenburg H70 Birth Cohort Studies in Sweden. Participants (n = 316, 70 years old) underwent comprehensive cognitive examinations, and CSF Aβ-42, Aβ-40, T-tau, and P-tau concentrations were measured. Participants were classified according to the ATN system, and according to their Clinical Dementia Rating (CDR) score. Cognitive performance was examined in the CSF amyloid, tau, and neurodegeneration (ATN) categories. Results: Among participants with CDR 0 (n = 259), those with amyloid (A+) and/or tau pathology (T+, N+) showed similar performance on most cognitive tests compared to participants with A-T-N-. Participants with A-T-N+ performed worse in memory (Supra span (p = 0.003), object Delayed (p = 0.042) and Immediate recall (p = 0.033)). Among participants with CDR 0.5 (n = 57), those with amyloid pathology (A+) scored worse in category fluency (p = 0.003). Conclusion: Cognitively normal participants with amyloid and/or tau pathology performed similarly to those without any biomarker evidence of preclinical AD in most cognitive domains, with the exception of slightly poorer memory performance in A-T-N+. Our study suggests that preclinical AD biomarkers are altered before cognitive decline.

scholarly journals Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease

Geriatrics ◽  
2018 ◽  
Vol 3 (2) ◽  
pp. 23 ◽  
Author(s):  
Catherine Roe ◽  
Ganesh Babulal ◽  
Sarah Stout ◽  
David Carr ◽  
Monique Williams ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Preclinical Alzheimer’S Disease

scholarly journals Baseline Results: The Association Between Cardiovascular Risk and Preclinical Alzheimer’s Disease Pathology (ASCEND) Study

2020 ◽  
Vol 75 (1) ◽  
pp. 109-117 ◽  
Author(s):  
Veena V. Kumar ◽  
Hanfeng Huang ◽  
Liping Zhao ◽  
Danielle D. Verble ◽  
Alexandra Nutaitis ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cardiovascular Risk ◽  
Preclinical Alzheimer’S Disease

scholarly journals Multimodal screening for neurodegeneration in preclinical Alzheimer’s disease using EEG, APOE4 genotype, neuropsychological and MRI data

2020 ◽  
Vol 16 (S5) ◽  
Author(s):  
Sinead Gaubert ◽  
Federico Raimondo ◽  
Marion Houot ◽  
Marie‐Constance Corsi ◽  
Lionel Naccache ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Preclinical Alzheimer’S Disease

scholarly journals Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept

2017 ◽  
Vol 13 (4) ◽  
pp. 454-467 ◽  
Author(s):  
Stéphane Epelbaum ◽  
Rémy Genthon ◽  
Enrica Cavedo ◽  
Marie Odile Habert ◽  
Foudil Lamari ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Preclinical Alzheimer’S Disease

O3-02-05: Proteomic identification of plasma biomarkers for hippocampal atrophy in Alzheimer's disease

2008 ◽  
Vol 4 ◽  
pp. T161-T161
Author(s):  
Madhav Thambisetty ◽  
Andrew Simmons ◽  
Abdul Hye ◽  
Darragh O'Brien ◽  
James Campbell ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Hippocampal Atrophy ◽  
Plasma Biomarkers ◽  
Proteomic Identification
Sign in / Sign up

Export Citation Format

Share Document